On March 14, 2024, Better Therapeutics announced that it is terminating its employees and will explore strategic alternatives, which could include a sale of the company and/or its assets as well as wind-down of the company. On March 18, 2024, Nasdaq suspended the company’s shares from trading on the Nasdaq Stock Market, and Nasdaq will delist the company once the applicable appeal periods have lapsed. Trading for the company's shares has transitioned to the OTC markets under the same ticker symbol.
Prescription Digital Therapeutics
Regulated and prescribed mobile applications, used under physician supervision, provide the delivery system for behavioral therapy
Cognitive Behavioral Therapy
To initiate, advance, and maintain behavioral change, our proprietary CBT targets cognitive patterns that drive eating and lifestyle behaviors
Evidence based treatment demonstrating statistically significant reductions in A1c after 180 days of use
- Trial Size
- 668
Participants completed onboarding in randomized controlled trial
- % Participants Improved
- 65%
Participants with A1c improvements
- A1c reduction
- 30%
Participants with A1c improvement of ≧ 1%
- Dose response
- 10x
Greater improvement in A1c in participants completing 20+ CBT lessons compared to those completing < 10
- Engagement
- 81%
Participants actively engaged at 6 months
- Satisfaction
- 61
NPS score after 180 days of use
Our lead therapeutic candidate in type 2 diabetes delivers cognitive behavioral therapy to enable changes in neural pathways of the brain and lead to lasting behavioral change.
